TIDMPOLB
RNS Number : 6634J
Poolbeg Pharma PLC
14 December 2022
Poolbeg Pharma plc
Poolbeg exclusively licences innovative oral delivery technology
for metabolic syndrome related diseases
Clinical trial to demonstrate technology can safely deliver
GLP-1 to commence in H1 2023
Prof Brendan Buckley joins Poolbeg's Scientific Advisory Board
to guide clinical development of technology
Licence expands Poolbeg's existing exclusive licence to AnaBio's
oral vaccine delivery technology
Investor Meet Company presentation on 14 December 2022 at
5:30pm
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the
'Company'), a leading infectious disease focused biopharmaceutical
company, announces that it has acquired an exclusive licence from
InsuCaps Limited ("InsuCaps"), a sister company of AnaBio
Technologies ("AnaBio"), to use InsuCaps' patented
microencapsulation and nanoencapsulation oral delivery technologies
in metabolic syndrome related diseases including obesity,
pre-diabetes and diabetes. Obesity alone costs the US healthcare
system c. $173bn a year.
Following the licence, in H1 2023 Poolbeg will rapidly commence
a proof-of-technology clinical trial to determine that a
Glucagon-like Peptide 1 receptor (GLP-1) agonist can be safely
delivered orally in humans. GLP-1 agonists, which are used to treat
diabetes and obesity, represent an extremely large, fast-growing
opportunity estimated to grow to c.$22bn per annum by 2025. At
present, all but one GLP-1 products are injectables, which are more
onerous for patients than oral delivery.
The upcoming trial is designed to provide data confirming that
the patented microencapsulation and nanoencapsulation technologies
can safely deliver GLP-1 orally, with results expected to be
announced later next year. In line with its rapid-partnering model,
Poolbeg then intends to licence the technology to pharma and
biotech for use in obesity and / or diabetes, as well as other
active molecules in metabolic syndrome related diseases.
This oral GLP-1clinical trial rapidly follows the completion of
Poolbeg's LPS challenge trial for POLB 001 and, like the LPS
challenge study, is in line with Poolbeg's efficient, capital light
approach to clinical development at the core of the Poolbeg
model.
This exclusive licence is in addition to Poolbeg's exclusive
license to AnaBio's microencapsulation and nanoencapsulation
technologies which underpins Poolbeg's Oral Vaccine Platform. As
recently announced, a Poolbeg-led consortium was awarded EUR2.3m in
non-dilutive funding by the Irish Government's Disruptive
Technologies Innovation Fund to progress the Oral Vaccine
Platform.
Addition to Poolbeg's Scientific Advisory Board
Poolbeg has also added Prof Brendan Buckley to its Scientific
Advisory Board. He is the former Chief Medical Officer at ICON plc,
a medical graduate of University College Cork and a doctoral
graduate in Biochemistry in the Faculty of Medicine at Oxford
University. Prof Buckley has advised Poolbeg since inception and
has deep experience in metabolic diseases including over 40 years'
experience in clinical practice as a Consultant Physician in
endocrinology, diabetes and in academic clinical pharmacology. In
addition, Brendan has sat on the European Medical Agency (EMA)'s
Scientific Advisory Group for Diabetes and Endocrinology. He has
published over 150 scientific papers, mainly on metabolic disease,
as well as the recent key opinion-leading book 'Re-Engineering
Clinical Trials'.
Investor Meet Company presentation - 14 December 2022 at
5:30pm
Jeremy Skillington, PhD, Chief Executive Officer, and Professor
Brendan Buckley will provide a live presentation via the Investor
Meet Company platform on 14 December 2022 at 5:30pm. Click here to
register .
The presentation is open to all existing and potential
shareholders. Investors can sign up to Investor Meet Company for
free and add to meet Poolbeg Pharma plc here . The presentation and
recording will be available on
the Company's website after the event here .
Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: "Poolbeg
saw the potential for microencapsulation and nanoencapsulation oral
delivery technologies in vaccines, and this has been further
validated by the grant from the Irish Government's Disruptive
Technologies Innovation Fund. Drawing on our growing understanding
of this technology from our Oral Vaccine Platform, we believe that
there is significant opportunity in other adjacent areas, such as
metabolic diseases. Diabetes and obesity are extremely fast growing
markets and the ability to administer drugs orally, rather than
through injection, will improve access and quality of life for
millions of patients. We are really excited to be moving swiftly to
a proof-of-concept trial in H1 2023 to test the oral delivery of
GLP-1 in humans, with the results to be announced later in the
year."
---
Dr Sinéad Bleiel, Founder & Chief Scientific Officer of
InsuCaps said: " We are excited to be expanding our working
relationship with Poolbeg and believe that the trial commencing in
H1 2023 will deliver meaningful data showing our ability to orally
deliver GLP-1 safely and efficiently. As the world is beginning to
realise, GLP-1 and similar metabolic peptides have life changing
effects for diabetics and are becoming the obesity management drug
of choice for the years ahead. We believe that our
microencapsulation and nanoencapsulation oral delivery technologies
can potentially deliver significant quality of life benefits to
patients suffering from these long-term metabolic syndrome
conditions."
-Ends-
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Mary Clark, Nick Bastin, Manel Mateus, poolbeg@optimumcomms.com
Vici Rabbetts
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in prevalent and emerging
infectious diseases. Poolbeg has a disciplined portfolio approach
to mitigate risk, accelerate drug development and enhance investor
returns. The Company simultaneously advances multiple programmes in
cost-effective clinical trials, rapidly generating early human
safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg also uses AI to interrogate human challenge trial data sets
to quickly identify new targets and drugs, and in-license near or
in the clinic medicines, leading to faster development and greater
commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from hVIVO plc (formerly Open Orphan
plc) , an industry leading infectious disease and human challenge
trials business, Poolbeg has access to knowledge, experience, and
clinical data from over 20 years of human challenge trials. The
Company is using these insights to acquire new assets as well as
reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg has a small
molecule immunomodulator for severe influenza (POLB 001) which has
completed its LPS human challenge trial with full data read-out
expected in Q2 2023; a first-in-class, intranasally administered
RNA-based immunotherapy for respiratory virus infections (POLB
002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is also developing two O ral Delivery Programmes and is
progressing two A rtificial I ntelligence (AI) P rogrammes to
accelerate the power of its human challenge model data and biobank,
with results from the first programme expected by year end.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
About Insucaps
InsuCaps is a specialist microencapsulation company, focussed on
improving health and performance through micro-encapsulation of
Active Pharmaceutical Ingredients for pharmaceutical
applications.
Microencapsulation represents a sophisticated delivery system
whereby a protective coat is created at microscopic level around
the API which protects it from a wide range of environmental
conditions, enables its release at the appropriate site within the
body, and thereby ensures that the health benefits of the API are
fully realised. InsuCaps has successfully applied this technology
for the oral delivery of injectable API's, ensuring protection
during tabletting and similar processing, maintaining the API
stability through the hostile environment of the stomach and
ensuring its successful transfer across the gut wall to deliver the
associated biological effect. The technology is protected via 16
patent families.
InsuCaps operates out of a 2000m(2) state of the art facility in
Cork, comprising R&D laboratories, pilot plant and production
facilities
For further information email aidan.fitzsimons@anabio.ie
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCQZLBFLLLEFBL
(END) Dow Jones Newswires
December 14, 2022 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024